Diagnosed with Cancer After Taking the Weight Loss Drug Belviq or Belviq XR?
If you or a loved one took Belviq or Belviq XR for weight-loss, you may be at increased risk for cancer including pancreatic, colorectal and lung cancer. You or your loved one may be entitled to compensation.
Belviq and Belviq XR Weight-Loss Drug Recalled
The U.S. Food and Drug Administration (FDA) has announced that Japanese drug maker, Eisai Inc. has agreed to voluntarily withdraw its weight-loss drugs Belviq (lorcaserin) and long-acting form, Belviq XR after study results showed a slight increased risk of cancer.
The FDA has recommended that patients should stop taking Belviq and should talk to their health care providers about alternative weight-loss medications or methods but is not recommending that patients get additional screening at this time.
The withdrawal of Belviq was requested by the FDA based on results of a 5-year study which examined 12,000 patients and showed that patients taking Belviq were diagnosed with cancer at higher rate than those taking placebo.
Belviq Cancer Study
On February 13, 2020, the FDA announced that the drug maker has agreed to withdraw Belviq from the U.S. market.
Belviq (lorcaserin) was approved for weight-loss in 2012 and its manufacturer, Japanese drug company, Eisai was required to conduct long-term safety studies into cardiac safety. In January of 2020, the FDA announced that they were reviewing results of the study which showed no heart risk but had indicated a possible cancer risk
The results of the five-year study showed an elevated overall cancer rate for the Belviq group compared to the placebo group with extended use. Reports of pancreatic, colorectal, and lung cancer were particularly elevated in Belviq users.
People who took Belviq or Belviq XR and were diagnosed with cancer may be eligible for compensation and should seek legal advice.
Contact a Belviq Cancer Attorney
If you or a loved one took Belviq or Belviq XR for weight-loss and have been diagnosed with pancreatic, colorectal or lung cancer, call us today at 747-283-1144 or fill out the free case evaluation form. All our consultations are free.